**Question:** A known sputum positive pulmonary tuberculosis patient currently on INH, rifampicin, pyrazinamide and ethambutol is found to be HIV positive. His CD4 count was 100/ L and viral load was more than 50,000 copies/ml. Which of the following antiretroviral drug should be avoided -

A. Tenofovir
B. Lamivudine
C. Zidovudine
D. Nevirapine

**Core Concept:** In HIV-infected patients, the use of antiretroviral therapy (ART) medications can lead to drug-drug interactions with tuberculosis (TB) medications, potentially compromising their efficacy and increasing the risk of drug resistance.

**Why the Correct Answer is Right:** Dolutegravir is a highly effective integrase inhibitor used in ART regimens. However, in the context of co-infection with TB, it can cause a significant interaction with rifampicin, one of the mainstay anti-TB drugs. This interaction results in decreased plasma levels of dolutegravir, reducing its efficacy in HIV treatment.

**Why Each Wrong Option is Incorrect:**

A. Tenofovir: This is a nucleoside reverse transcriptase inhibitor (NRTI) not associated with significant interactions with TB medications, making it an appropriate choice for ART in TB-HIV co-infected patients.
B. Lamivudine: Another NRTI, similar to Tenofovir, Lamivudine is not known to cause significant interactions with TB medications, so it is a suitable option for ART in TB-HIV co-infected patients.
C. Zidovudine: A nucleoside reverse transcriptase inhibitor (NRTI), Zidovudine, can have significant interactions with rifampicin, which is crucial in TB treatment. Using Zidovudine in TB-HIV co-infected patients can lead to reduced plasma levels of Zidovudine, compromising its effectiveness in HIV treatment.
D. Nevirapine: Nevirapine is an efavirenz analogue used in ART regimens. It has significant interactions with rifampicin, a crucial TB medication. The interaction results in decreased plasma levels of Nevirapine, making it an unsuitable option for HIV treatment in TB-HIV co-infected patients.

**Clinical Pearl:** When treating TB-HIV co-infection, it is crucial to minimize interactions between ART drugs and TB medications to maintain the efficacy of both treatments. This is why Tenofovir and Lamivudine are preferred over Nevirapine and Zidovudine due to their potential interactions with rifampicin.

**Why Tenofovir and Lamivudine are suitable:** Tenofovir and Lamivudine are NRTIs (Nucleoside Reverse Transcriptase Inhibitors), which are generally well-tolerated and have minimal interactions with rifampicin, a key component of TB treatment. This ensures that both TB and HIV treatments are maintained at optimal levels, reducing the risk of treatment failure and drug resistance.

**Why Dolutegravir and Raltegravir are